Skip to main content
. 2022 Jan 31;7(3):215–221. doi: 10.1136/svn-2021-001030

Table 3.

Premortem-diagnosed and postmortem-diagnosed thromboembolic events (thrombosis in the femoral vein or in the periprostatic or periuterine venous plexus, embolus in the lung)

Number of patients Antithrombotic therapy Length of hospital stay (from admission until death)
Premortem-diagnosed thromboembolic events 80 31* 13.0 (8.0–21.0)
Postmortem-diagnosed thromboembolic events 80 12† 8.0 (5.0–13.0)

*Forty-nine patients did not receive antithrombotic therapy (eg, due to the risk of haemorrhagic transformation of an infarct, enlargement of parenchymal haemorrhage, concomitant systemic bleeding, etc).

†Sixty-eight patients were not administered antithrombotic treatment partly due to the lack of clinical symptoms, and partly due to the fear of haemorrhagic transformation of an infarct and the fact that they had large parenchymal haemorrhage and terminal state.